Marshall Wace
LTRN icon

Marshall Wace’s Lantern Pharma LTRN Stock Holding History

Marshall Wace’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.8K Buy
+11,946
New +$35K ﹤0.01% 2992

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Marshall Wace's LTRN Position: Q2 2026 in Review

Marshall Wace opened a new position in Lantern Pharma (LTRN) in Q2 2026: 11,946 shares worth $49.8K. The stake represents ﹤0.01% of the portfolio and ranks #2992 among its holdings.

39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Marshall Wace held 11,946 shares of Lantern Pharma worth $49.8K as of Q2 2026.
  • Lantern Pharma was a new Marshall Wace position in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2992 holding.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.